XpresCheck™ Provides Business Update
XpresSpa Group, Inc. (Nasdaq: XSPA), a health and wellness company,
today provided a business update on XpresCheck™.
XpresCheck will begin rapid testing for COVID-19
at both JFK International Airport and Newark Liberty International
Airport tomorrow, Wednesday, October 7, 2020. Rapid Testing
represents an expansion of XpresCheck’s COVID-19 testing options
which already include the Polymerase Chain Reaction (PCR) Test and
Blood Antibody Test. Rapid testing will also be available at all
future XpresCheck locations after opening.
“We believe rapid COVID-19 testing at airports
can play a major role in slowing the virus spread and decreasing
the risk of new community outbreaks linked to travel as cases
continue to rise throughout many states,” said Doug Satzman,
XpresSpa Group CEO. “We are pleased to now offer Abbott’s portable,
rapid molecular ID NOW COVID-19 test, which has emerged as a
critical tool in the fight against COVID-19 by delivering
on-the-spot results in a matter of minutes. Having a rapid test
inside the airport immediately upon travel could also eliminate the
need for a full 14-day quarantine in states where that
The Abbott ID NOW is a rapid molecular
point-of-care test that delivers COVID-19 results within 13
minutes. About the size of a small kitchen appliance, ID NOW’s
rapid results and compact design help make testing for active
COVID-19 infections more accessible in non-traditional settings.
Giving people real-time results about their COVID-19 status means
they can more confidently go about their daily lives.
Other Business Updates
- XpresCheck is working with major
airlines to support creation of potential air bridges between U.S.
cities and international destinations, including, but not limited
to, New York to London.
- XpreCheck is engaged in discussions
with multiple emerging Health Passport Apps which would link
COVID-19 test results from its partnered labs directly into these
apps. Passengers would then be able to show their test results
through these apps to airlines and destinations so as to ensure a
hassle-free entry and avoid quarantines, where applicable
The ID NOW COVID-19 test has not been FDA
cleared or approved. It has been authorized by the FDA under an
emergency use authorization for use by authorized laboratories and
patient care settings. The test has been authorized only for the
detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens, and is only authorized for the duration of
the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostic tests for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is
terminated or revoked sooner.
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a global health and wellness
holding company. XpresSpa Group’s core asset, XpresSpa, is a
leading airport retailer of spa services and related health and
wellness products, with 50 locations in 25 airports globally.
Through its XpresTest, Inc. subsidiary, the Company also provides
COVID-19 screening and testing under its XpresCheck™ brand at JFK
International Airport and Newark Liberty International Airport. To
learn more about XpresSpa Group, visit: www.XpresSpaGroup.com. To
learn more about XpresSpa, visit www.XpresSpa.com. To learn more
about XpresCheck, visit www.XpresCheck.com.
Forward-Looking Statements This
press release may contain "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. These include
statements preceded by, followed by or that otherwise include the
words "believes," "expects," "anticipates," "estimates,"
"projects," "intends," "should," "seeks," "future," "continue," or
the negative of such terms, or other comparable terminology. In
particular, these statements include, without limitation,
statements about our future operating or financial performance,
market opportunity and growth strategy, in particular statements
about our expectations relating to our new XpresCheck™ concept, our
ability to identify and convert spa locations to XpresCheck™ sites
on a timely and cost-efficient basis, being able to expand testing
to other communicable diseases as well as administer vaccinations
for the seasonal flu, our positioning to be part of the national
rollout of a COVID-19 vaccination when it becomes available
(including whether such vaccination becomes available in the near
term or at all), the degree to which our public testing model
assists passengers meet testing requirements in select states and
countries, our ability to identify and gain access to the latest
and best COVID-19 testing methodologies and equipment, and our
ability expand our initial sites at JFK International Airport and
Newark Liberty International Airport as we currently expect, and
our overall ability to manage the regulatory challenges associated
with this business line. Forward-looking statements relating to
expectations about future results or events are based upon
information available to XpresSpa Group as of today's date and are
not guarantees of the future performance of the company, and actual
results may vary materially from the results and expectations
discussed. Additional information concerning these and other risks
is contained in XpresSpa Group’s most recently filed Annual Report
on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports
on Form 8-K and other Securities and Exchange Commission filings.
All subsequent written and oral forward-looking statements
concerning XpresSpa Group, or other matters and attributable to
XpresSpa Group or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements above.
XpresSpa Group does not undertake any obligation to publicly update
any of these forward-looking statements to reflect events or
circumstances that may arise after the date hereof.
Investor Relations: Raphael
Gross, ICR email@example.com